Structural Cardiotoxicity - Troponin Detection

Cardiotoxicity is a major cause of drug attrition in preclinical and clinical drug development. Our Biomarker Service offers an early structural cardiotoxicity assay based on fully validated and functional human iPSC-derived cardiomyocytes and is suitable for high-throughput safety and toxicity screening of compounds.

What are your benefits?

Clinically relevant Troponin I biomarker
Currently most widely used biomarker for detection of myocardial damage in patients

High sensitivity
Detection as low as 10 pg/mL

Kinetic compound analysis
Enabled by the non-destructive nature of the assay

Enabling multiplexed assays
Compatible with a wide range of electrophysiology assays such as MEA, impedance or Ca2+-flux


Cardiotoxicity is a major cause of drug attrition in preclinical and clinical drug development. Drug-induced cardiotoxicity can be functional or structural in nature, and can be developed in a short-term or long-term manner. Investigation of both structural as well as functional toxicity ensures a better prediction of induced cardiotoxic risks. Structural cardiotoxicity can be determined by detection of the secreted cardiac specific marker Troponin I, which is released into circulation after cardiomyocyte damage induced by myocardial infarct or after treatment with cardiotoxic drugs.

For a more comprehensive assessment of predicting cardiotoxicity, this assay can be multiplexed with any functional readout including microeletrode array (MEA), impedance or calcium transient assays.

Instead of secreted Troponin I also other biomarkers can be detected upon request.


Service specifications

Cell type

Human iPSC-derived cardiomyocytes

Service type

Structural toxicity based on biomarker detection


96 wells (Up to 384 wells possible)

Time points

16, 24, 40, 48 and 64 hours after compound addition

Compound concentration*

0.1, 1, 10 µM in medium + 0.1% DMSO

Positive control


Vehicle control

0.1% DMSO


Released Troponin I detection


3 Weeks for up to 9 compounds (in triplicates)


A study protocol will be agreed before study initiation. Results will be presented in a study report.

* Suggested concentrations, to be agreed with client


Would you like to know more about our Structural Cardiotoxity Detection Service, or any of our other services?

We're here to listen to your project plans, questions and challenges, and to co-develop a solution that fits your specifications. Please leave your details and message in the form below and we will get back to you as soon as possible.